Search results for "Bridged-Ring Compounds"

showing 9 items of 19 documents

SNPs and taxane toxicity in breast cancer patients

2014

Aim: In order to identify genetic variants associated with taxanes toxicity, a panel with 47 SNPs in 20 genes involved in taxane pathways was designed. Patients & methods: Genomic DNA of 113 breast cancer patients was analyzed (70 taking docetaxel, 43 taking paclitaxel). Results: Two SNPs associated with docetaxel toxicity were identified: CYP3A4*1B with infusion-related reactions; and ERCC1 Gln504Lys with mucositis (p ≤ 0.01). Regarding paclitaxel toxicity: CYP2C8 HapC and CYP2C8 rs1934951 were associated with anemia; and ERCC1 Gln504Lys with neuropathy (p ≤ 0.01). Conclusion: Genes involved in DNA repair mechanisms and reactive oxygen species levels influence taxane toxicity in cance…

Bridged-Ring CompoundsMucositisOncologymedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsPaclitaxelmedicine.medical_treatmentBreast NeoplasmsDocetaxelPharmacologyPolymorphism Single Nucleotidechemistry.chemical_compoundBreast cancerInternal medicineGeneticsMucositisCytochrome P-450 CYP3AHumansMedicineGenetic Association StudiesAgedPharmacologyChemotherapyTaxanebusiness.industryCancerMiddle AgedEndonucleasesmedicine.diseaseDNA-Binding ProteinsDocetaxelPaclitaxelchemistryMolecular MedicineFemaleTaxoidsERCC1businessmedicine.drugPharmacogenomics
researchProduct

Relationship Between Thymidylate Synthase and p53 and Response to FEC Versus Taxane Adjuvant Chemotherapy for Breast Carcinoma

2011

Many drugs can be used for adjuvant therapy of breast cancer, including anthracyclines, cyclophosphamide, 5-fluorouracil (5-fU) and, recently, taxanes (TXT) have shown promising results. 5-FU blocks thymidylate synthase (TS) which cross-links p53 mRNA, inhibiting its synthesis. TS overexpression is one of the main mechanisms involved in 5-FU drug resistance. Enough p53 mutations can confer resistance to chemotherapy using anthracyclines and 5-FU, while are associated with improved responses to TXT. The aim of this study was to examine the TS and p53 levels in tumor samples and to compare the efficacy of FEC (5-FU, epirubicin, cyclophosphamide) and TXT chemotherapy in a group of patients wit…

Bridged-Ring CompoundsOncologymedicine.medical_specialtyCyclophosphamidemedicine.medical_treatmentBreast NeoplasmsThymidylate synthaseBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineAdjuvant therapyHumansPharmacology (medical)CyclophosphamideEpirubicinNeoplasm StagingPharmacologyChemotherapyTaxanebiologybusiness.industryThymidylate SynthasePrognosismedicine.diseaseImmunohistochemistryInfectious DiseasesOncologyChemotherapy AdjuvantFluorouracilbiology.proteinCancer researchFemaleTaxoidsFluorouracilTumor Suppressor Protein p53businessmedicine.drugEpirubicinJournal of Chemotherapy
researchProduct

Hirsutane-Type Sesquiterpenes with Uncommon Modifications from Three Basidiomycetes

2010

From three basidiomycetes, Xeromphalina sp., Stereum sp., and Pleurocybella porrigens, six triquinane sesquiterpenes with unprecendented modifications and a rearranged sesquiterpene related to coriolin C have been isolated. Their isolation, structure elucidation, and biological evaluation are described.

Bridged-Ring CompoundsPolycyclic SesquiterpenesAntifungal AgentsBacteriaMolecular StructurebiologyStereochemistryXeromphalinaBasidiomycotaOrganic ChemistryFungibiology.organism_classificationSesquiterpenePleurocybella porrigensTerpenoidAnti-Bacterial Agentschemistry.chemical_compoundchemistryOrganic chemistryStereumSesquiterpenesBiological evaluationThe Journal of Organic Chemistry
researchProduct

Halloysite nanotubes loaded with peppermint essential oil as filler for functional biopolymer film

2016

Abstract The purpose of this paper is to show how a functional bionanocomposite film with both antioxidant and antimicrobial activities was successfully prepared by the filling of a pectin matrix with modified Halloysite nanotubes (HNT) containing the essential peppermint oil (PO). Firstly, HNT surfaces were functionalized with cucurbit[6]uril (CB[6]) molecules with the aim to enhance the affinity of the nanofiller towards PO, which was estimated by means of HPLC experiments. The HNT/CB[6] hybrid was characterized by several methods (thermogravimetry, FT-IR spectroscopy and scanning electron microscopy) highlighting the influence of the supramolecular interactions on the composition, therma…

Bridged-Ring CompoundsStaphylococcus aureusHalloysite nanotubes; Nanocomposite food packaging; Essential oil; Pectin; Antimicrobial and antioxidant propertiesfood.ingredientPolymers and PlasticsPectinHalloysite nanotube02 engineering and technologyengineering.material010402 general chemistry01 natural sciencesHalloysiteEssential oilNanocompositesContact anglefoodNanocomposite food packagingMaterials ChemistryEscherichia coliOrganic chemistryPlant OilsAntimicrobial and antioxidant propertiesAntimicrobial and antioxidant propertieSettore CHIM/02 - Chimica FisicaNanocompositeNanotubesChemistryOrganic ChemistryImidazolesMembranes ArtificialMentha piperitaSettore CHIM/06 - Chimica Organica021001 nanoscience & nanotechnologyPectin0104 chemical sciencesAnti-Bacterial AgentsThermogravimetrySolventChemical engineeringBiofilmsengineeringClayPectinsAluminum SilicatesBiopolymerBiocomposite0210 nano-technology
researchProduct

Effects of thrombin and of the phospholipase C inhibitor, D609, on the vascularity of the chick chorioallantoic membrane.

2000

Abstract Microvascular corrosion casting was used to assess the effects of thrombin and D609, a phospholipase C inhibitor, on the vascularity of the chick embryo chorioallantoic membrane (CAM). Discs containing vehicle, thrombin or D609 were placed on the CAM of fertilized white Leghorn eggs on Day 9 of gestation and vascularity was assessed on Day 11. Thrombin caused significant increases in the numbers (43%), diameters (5%) and lengths (17%), of both pre- and postcapillaries (first-order vessels by centripetal ordering). Conversely, D609 caused a decrease in the numbers (27%), lengths (12%) and diameters (8%) of first-order vessels. D609 decreased the total vascular volume of first- to th…

Bridged-Ring Compoundsmedicine.medical_specialtyanimal structuresAngiogenesisPhosphodiesterase InhibitorsNeovascularization PhysiologicChick EmbryoBiologyHemostaticsMicrocirculationThrombinVascularityAllantoisThiocarbamatesInternal medicinemedicineAnimalsOvumPharmacologyBlood VolumePhospholipase CThrombinThionesChorionNorbornanesChorioallantoic membraneEndocrinologymedicine.anatomical_structureType C PhospholipasesCirculatory systemMicroscopy Electron Scanningmedicine.symptommedicine.drugBlood vesselGeneral pharmacology
researchProduct

Assessing the impact of CMF-like/Anthracycline-based/Anthracycline-Taxane-based/dose-dense chemotherapy in dependency of positive axillary lymph node…

2014

Abstract Aim Adjuvant chemotherapy has changed dramatically in the last decades. Anthracycline-/Taxane-based and dose-dense chemotherapy regimens improved survival in node positive breast cancer. This study tries to answer the following questions: (1)Are there differences in survival dependent on chemotherapy regimens in stratified by number of positive lymph nodes/grading (G)/hormone receptor-status (HR)/T-stage? (2)Is it possible to attribute these effects to chemotherapy by only investigating patients who received 100% guideline-conform surgery, radiotherapy and endocrine therapy? Methods This is a German multi-centre (17 participating hospitals all certified as breast cancer centres) re…

OncologyAdultBridged-Ring CompoundsCancer Researchmedicine.medical_specialtyNeoplasms Hormone-DependentAxillary lymph nodesAnthracyclineDose-dense chemotherapyReceptor ErbB-2medicine.medical_treatmentBreast NeoplasmsDisease-Free SurvivalYoung AdultBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansAnthracyclinesAgedRetrospective StudiesAged 80 and overChemotherapyAnalysis of VarianceTaxanebusiness.industryRetrospective cohort studyMiddle Agedmedicine.diseaseSurgeryRadiation therapymedicine.anatomical_structureTreatment OutcomeOncologyChemotherapy AdjuvantLymphatic MetastasisPractice Guidelines as TopicFemaleTaxoidsGuideline AdherencebusinessEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Optimizing taxane use in MBC in the emerging era of targeted chemotherapy.

2013

The first-generation taxanes, conventional paclitaxel and docetaxel, are established treatment options for adjuvant and metastatic breast cancer (MBC). However, these agents have limitations, including primary/secondary resistance and harsh toxicities. The introduction of paclitaxel albumin represents a significant advance in taxane therapy as the first of a new generation of taxanes. This agent utilizes albumin pathways to achieve enhanced and targeted drug delivery to the tumour. The lack of solvent also means that it is well tolerated, despite the lack of premedications. Paclitaxel albumin is licensed in the United States and Europe as ≥2nd-line therapy in MBC (260mg/m(2) once every thre…

OncologyBridged-Ring Compoundsmedicine.medical_specialtymedicine.medical_treatmentAntineoplastic AgentsBreast NeoplasmsPharmacologychemistry.chemical_compoundBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansMolecular Targeted TherapyNeoplasm MetastasisChemotherapyClinical Trials as TopicTaxanebusiness.industryHematologymedicine.diseaseMetastatic breast cancerTreatment OutcomeOncologyPaclitaxelchemistryTargeted drug deliveryDocetaxelFemaleTaxoidsbusinessAdjuvantmedicine.drugCritical reviews in oncology/hematology
researchProduct

The Impact of Age on Quality of Life in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Comparative Analysis From the Prospective Multicent…

2016

Elderly breast cancer patients are affected by poorer quality of life (QoL) compared to younger patients. Because QoL has a relevant impact on guideline-adherent treatment, elderly breast cancer patients are often undertreated, especially with regard to adjuvant chemotherapy, and overall survival is decreased. Thus, understanding the impact of chemotherapy on QoL in elderly patients is crucial. This study compared QoL in patients aged 65 years and 65 to 70 years receiving adjuvant chemotherapy as a secondary outcome in the prospective randomized multicenter ADEBAR trial.Patients with lymph node-positive breast cancer were prospectively randomized for either sequential anthracycline-taxane o…

OncologyCancer ResearchDocetaxel0302 clinical medicineQuality of lifeSurveys and QuestionnairesAntineoplastic Combined Chemotherapy ProtocolsMulticenter Studies as TopicAnthracyclinesLongitudinal StudiesProspective Studies030212 general & internal medicineYoung adultProspective cohort studyAntibiotics AntineoplasticAge FactorsMiddle AgedhumanitiesOncologyDocetaxelChemotherapy Adjuvant030220 oncology & carcinogenesisPractice Guidelines as TopicFemaleTaxoidsFluorouracilmedicine.drugEpirubicinAdultBridged-Ring Compoundsmedicine.medical_specialtyAdolescentCyclophosphamideBreast NeoplasmsYoung Adult03 medical and health sciencesBreast cancerInternal medicinemedicineHumansCyclophosphamideAgedEpirubicinbusiness.industryCancermedicine.diseaseClinical Trials Phase III as TopicQuality of LifePatient CompliancebusinessClinical Breast Cancer
researchProduct

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study

2018

Background: Chemotherapy plus 1-year trastuzumab is the standard adjuvant treatment of HER2-positive breast cancer. The efficacy of less extended trastuzumab exposure is under investigation. The short-HER study was aimed to assess the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy. Patients and methods: HER2-positive breast cancer patients with node-positive or, if node negative, with at least one risk factor (pT>2 cm, G3, lympho-vascular invasion, Ki-67 > 20%, age 35 years, or hormone receptor negativity) were randomly assigned to receive sequential anthracycline-taxane combinations plus 1-year trastuzumab (arm A, long) or plus 9 weeks tra…

OncologyTime FactorsAdjuvant Breast cancer Cardiac safety De-escalated treatment TrastuzumabSettore MED/06 - Oncologia MedicaReceptor ErbB-2medicine.medical_treatmentAnthracycline030204 cardiovascular system & hematologyBreast cancerAntineoplastic Agents ImmunologicalErbB-20302 clinical medicineTrastuzumabAntineoplastic Combined Chemotherapy ProtocolsClinical endpointAnthracyclinesskin and connective tissue diseasesAdjuvantMastectomyAdjuvant; Breast cancer; Cardiac safety; De-escalated treatment; Trastuzumab;Hazard ratioHematologyMiddle AgedChemotherapy regimenBridged-Ring CompoundImmunologicalLocalOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleTaxoidsTrastuzumab adjuvant breast cancer cardiac safety de-escalated treatmentBreast NeoplasmMastectomyHumanReceptormedicine.drugAdultBridged-Ring Compoundsmedicine.medical_specialtyTime FactorSocio-culturaleBreast NeoplasmsAntineoplastic AgentsDe-escalated treatmentDisease-Free SurvivalDrug Administration Schedule03 medical and health sciencesBreast cancerTaxoidInternal medicinemedicineHumansChemotherapyRisk factorAgedNeoplasm StagingChemotherapyAntineoplastic Combined Chemotherapy ProtocolCardiac safetybusiness.industryTrastuzumabAdjuvant; Breast cancer; Cardiac safety; De-escalated treatment; Trastuzumab; Hematology; Oncologymedicine.diseaseCardiotoxicityNeoplasm RecurrenceNeoplasm Recurrence LocalbusinessAnnals of Oncology
researchProduct